University of California San Francisco
Give to UCSFA new UCSF study reports for the first time that significant hearing issues often occur among adult survivors of the most common forms of cancer.
A world-class team of researchers co-led by UCSF’s Allan Balmain, PhD, FRS, has been selected to receive a $25 million Cancer Grand Challenges award to investigate the very early stages of cancer development.
In a groundbreaking finding, a new study led by UCSF found that routine screening for and removal of precancerous anal lesions can significantly reduce the risk of anal cancer, similar to the way cervical cancer is prevented in women.
When Cheryl Broyles was diagnosed with glioblastoma, her goal was to outlive the disease’s 15-month prognosis. That was 22 years ago. Broyles’ survival has been the result of luck, tumor location, and cutting-edge treatment and diagnostics.
For many women, breast cancer screening with a three-dimensional imaging technique called digital breast tomosynthesis (DBT) may not offer advantages over digital mammography, but for some it may reduce the chance of an advanced cancer diagnosis, according to a new JAMA study.
UCSF Benioff Children’s Hospitals have been recognized among the nation’s best pediatric medical centers in all 10 specialties assessed in U.S. News & World Report's Best Children’s Hospitals 2022-23, reflecting the caliber of specialty care the hospitals provide.
A personal essay about finding joy amid the uncertainty of cancer.
A less meticulous physician might have mistaken the man’s complaints for run-of-the-mill vascular disease. Not UCSF resident Ori Lieberman.
Companies claim there’s bad stuff in our homes and bodies, and we should pay to purge it. What’s worth worrying over?
As a worldwide shortage of contrast dye for medical imaging continues, a new UCSF research letter in JAMA quantified strategies to safely reduce dye use in computed tomography (CT) by up to 83%. CT is the most common use for the dye.
UCSF research scientists and statisticians have developed improved biomarker classifications as part of their research results in the I-SPY 2 trial for high-risk breast cancer patients. The new cancer response subtypes reflect responsiveness to drug treatments and are intended to help clinicians be more precise in how they target therapies.